Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.2% 1.2%   Bankruptcy risk   1.2% 1.7% 1.9% 2.1% 2.4% 1.8% 7.9% 7.9%   Credit score (0-100)   83 74 70 65 63 70 31 31   Credit rating   A A A BBB BBB A BB BB   Credit limit (kDKK)   231.9 11.7 4.7 1.1 0.2 15.3 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   27,833 26,958 34,797 44,686 55,810 64,002 0.0 0.0   EBITDA   1,789 2,092 2,645 3,986 3,578 4,057 0.0 0.0   EBIT   1,771 2,049 2,622 3,939 3,524 4,008 0.0 0.0   Pre-tax profit (PTP)   1,764.3 2,030.9 2,637.0 3,845.7 3,493.4 4,002.2 0.0 0.0   Net earnings   1,376.1 1,584.1 2,056.9 2,999.6 2,723.2 3,114.1 0.0 0.0   Pre-tax profit without non-rec. items   1,764 2,031 2,637 3,846 3,493 4,002 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   32.8 30.5 19.8 118 63.7 14.8 0.0 0.0   Shareholders equity total   4,860 6,444 8,501 11,501 14,224 17,338 17,258 17,258   Interest-bearing liabilities   0.0 223 769 835 793 17,354 0.0 0.0   Balance sheet total (assets)   10,261 10,129 13,971 17,630 18,398 39,034 17,258 17,258   Net Debt   -613 -640 161 295 -2,403 15,833 -17,258 -17,258     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   27,833 26,958 34,797 44,686 55,810 64,002 0.0 0.0   Gross profit growth   7.7% -3.1% 29.1% 28.4% 24.9% 14.7% -100.0% 0.0%   Employees   29 34 37 47 57 63 0 0   Employee growth %   -9.4% 17.2% 8.8% 27.0% 21.3% 10.5% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   10,261 10,129 13,971 17,630 18,398 39,034 17,258 17,258   Balance sheet change%   34.0% -1.3% 37.9% 26.2% 4.4% 112.2% -55.8% 0.0%   Added value   1,788.9 2,092.2 2,644.8 3,985.9 3,570.4 4,056.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -13 -45 -33 52 -109 -98 -15 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   6.4% 7.6% 7.5% 8.8% 6.3% 6.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   19.8% 20.1% 22.1% 24.9% 19.7% 14.1% 0.0% 0.0%   ROI %   42.4% 32.9% 27.0% 28.9% 23.5% 16.3% 0.0% 0.0%   ROE %   33.0% 28.0% 27.5% 30.0% 21.2% 19.7% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   47.4% 63.6% 60.8% 65.2% 77.3% 44.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -34.3% -30.6% 6.1% 7.4% -67.1% 390.3% 0.0% 0.0%   Gearing %   0.0% 3.5% 9.0% 7.3% 5.6% 100.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   945.1% 19.1% 5.0% 11.7% 5.8% 0.6% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.9 3.7 5.2 5.3 4.4 1.8 0.0 0.0   Current Ratio   1.9 3.7 5.2 5.3 4.4 1.8 0.0 0.0   Cash and cash equivalent   613.5 862.3 608.1 539.3 3,195.5 1,520.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   4,827.3 7,364.0 11,274.3 14,206.9 14,160.2 17,323.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   62 62 71 85 63 64 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   62 62 71 85 63 64 0 0   EBIT / employee   61 60 71 84 62 64 0 0   Net earnings / employee   47 47 56 64 48 49 0 0